American Vanguard Earnings Call Transcripts
Fiscal Year 2026
-
Q2 2026 saw sales and EBITDA decline versus last year, but gross margin and specialty business grew, offsetting international weakness. Cost controls, new product investment, and pricing actions support confidence in meeting 2026 guidance and long-term growth targets.
-
The meeting confirmed the election of seven directors, ratified Deloitte as auditor, and approved annual advisory votes on executive compensation. Strategic plans focus on operational excellence, capital structure, and achieving $600M+ revenue by 2028 despite ongoing market challenges.
-
Net sales rose 7% to $124 million in Q1 2026, driven by strong U.S. crop and specialty product growth, while adjusted EBITDA surged 245% to $10.3 million. Strategic manufacturing shifts, new product initiatives, and a revamped capital structure position the company for continued margin and revenue expansion.
Fiscal Year 2025
-
2025 saw flat adjusted EBITDA and a 6% sales decline, but cost savings and operational improvements offset some headwinds. New product launches and facility rationalizations are expected to drive growth, with 2026 guidance targeting higher sales and EBITDA.
-
Adjusted EBITDA surged over 350% year-over-year, with gross margin up 300 basis points and operating costs down 11% for the quarter. Full-year adjusted EBITDA guidance is $40M-$44M, with a focus on debt reduction and a robust product pipeline expected to drive future growth.
-
Q2 2025 saw improved sales, nearly doubled adjusted EBITDA, and higher gross margins, driven by cost cuts and operational efficiencies. Management reaffirmed full-year guidance and expects continued margin expansion and debt reduction.
-
Q1 2025 revenue fell 14% year-over-year to $116 million, with adjusted EBITDA at $3 million. Cost controls and working capital improvements offset some headwinds from destocking, product removals, and market weakness. Full-year guidance was lowered, but signs of recovery are emerging.
-
New leadership is driving a transformation plan focused on operational efficiency, margin expansion, and growth in biologicals. The company targets a 15% EBITDA margin, improved plant utilization, and a stronger balance sheet, with 2025 guidance showing revenue and EBITDA growth.
Fiscal Year 2024
-
2024 adjusted revenue and EBITDA declined year-over-year but met guidance, with significant non-recurring charges positioning the company for future growth. 2025 guidance anticipates modest sales and margin improvement, with transformation efforts and debt reduction as key priorities.
-
Q3 sales and EBITDA declined year-over-year, mainly due to lower Aztec and Folex sales, but non-crop and Green Solutions segments showed strong growth. Full-year guidance for Adjusted EBITDA and sales is maintained, with optimism for a strong Q4 and ongoing business transformation benefits.
-
Q2 2024 saw lower sales and margins amid a weak ag economy, prompting a leadership overhaul, cost-cutting, and a revised outlook. Full-year guidance was reduced, with a focus on transformation, liquidity, and a 15% EBITDA margin target by 2026.